CLINICAL TRIALS PROFILE FOR RISPERDAL CONSTA
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Risperdal Consta
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | Icahn School of Medicine at Mount Sinai | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
| NCT00094926 ↗ | A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes. | Completed | Janssen, LP | Phase 3 | 2004-05-01 | The purpose of this study is to examine the safety and effectiveness of the long acting injectable form of the atypical antipsychotic Risperidone (Risperdal CONSTA), along with treatment as usual (TAU), in bipolar disorder patients who had more than 4 mood episodes in the past year. |
| NCT00094926 ↗ | A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes. | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2004-05-01 | The purpose of this study is to examine the safety and effectiveness of the long acting injectable form of the atypical antipsychotic Risperidone (Risperdal CONSTA), along with treatment as usual (TAU), in bipolar disorder patients who had more than 4 mood episodes in the past year. |
| NCT00130923 ↗ | Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder | Completed | Janssen, LP | Phase 4 | 2005-09-01 | The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder. |
| NCT00130923 ↗ | Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder | Completed | Dartmouth-Hitchcock Medical Center | Phase 4 | 2005-09-01 | The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Risperdal Consta
Condition Name
Clinical Trial Locations for Risperdal Consta
Trials by Country
Clinical Trial Progress for Risperdal Consta
Clinical Trial Phase
Clinical Trial Sponsors for Risperdal Consta
Sponsor Name
